GondolaBio · 4 weeks ago
Senior/Principal Scientist, Oligonucleotide Discovery (siRNA/ASO)
Palo Alto,CA,US
Full-time
Onsite
Senior Level, Lead/Staff
$185K/yr - $215K/yr
8+ years expGondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. They are seeking a Senior/Principal Scientist in Oligonucleotide Discovery to lead preclinical safety and pharmacology studies, collaborate with cross-functional teams, and provide scientific oversight on oligonucleotide programs.
BiotechnologyManufacturingPharmaceutical
Responsibilities
Lead the integration and interpretation of preclinical safety and pharmacology data, with a strong focus on off-target effects to inform program decisions
Partner closely with toxicology and biology teams to distinguish target-related versus off-target findings, assess dose-limiting toxicities, and evaluate overall therapeutic index and risk profile
Identify data gaps, recommend mechanistic or follow-up studies, and support risk mitigation strategies based on preclinical safety findings
Provide scientific oversight of CRO-executed studies, including preclinical safety, in vivo pharmacology, and supporting studies relevant to oligonucleotide programs
Review and provide input on study designs, protocols, data packages, and final reports to ensure scientific rigor, relevance, and alignment with program objectives
Serve as a primary scientific point of contact with external partners to ensure clear communication, high-quality execution, and timely delivery
Contribute to scientific evaluation of oligonucleotide DMPK data, including pharmacokinetics, biodistribution, tissue uptake, and durability of effect
Collaborate closely with DMPK teams to assess exposure–response and PK/PD relationships, and to contextualize safety findings relative to systemic and tissue-level exposure
Integrate DMPK insights into cohesive preclinical and translational narratives that support candidate selection and development planning
Collaborate closely with chemistry, DMPK, toxicology, translational, and clinical teams to support data-driven program decisions
Clearly summarize and communicate complex preclinical datasets in team meetings and governance forums
Serve as a senior scientific contributor to siRNA and/or ASO programs, providing expert understanding of oligonucleotide design strategies, chemistry, and biology without direct hands-on design or assay development responsibilities
Critically review and contextualize oligo design, modification strategies, and conjugation approaches proposed by internal teams and external partners
Qualification
Required
Ph.D. in molecular biology, pharmacology, chemistry, or a related field, or equivalent advanced degree
8+ years of industry experience in oligonucleotide drug discovery and/or development (siRNA and/or ASO strongly preferred)
Demonstrated hands-on experience in oligo design, assay development, and in vitro/in vivo pharmacology
Prior experience contributing to programs advancing toward IND
Familiarity with oligonucleotide DMPK concepts, including PK/PD and biodistribution
Experience managing and collaborating with external CROs
Strong data analysis, presentation, and scientific communication skills
Preferred
Exposure to conjugated oligos (e.g., GalNAc or other ligand-based approaches)
Experience supporting translational or biomarker-related studies
Experience across both siRNA and ASO modalities
Chinese Mandarin language proficiency (spoken and/or written) is a plus
Prior experience in a small or fast-growing biotech environment
Benefits
Robust and market-competitive compensation & benefits package (Base, Performance Bonus, Equity, health, welfare & retirement programs)
Flexible PTO
Rapid career advancement for strong performers
Partnerships with leading institutions
Commitment to Diversity, Equity & Inclusion
Company
GondolaBio
GondolaBio researches, develops and manufactures pharmaceutical products. It is a sub-organization of BridgeBio.
11-50 employees
Funding
Current Stage
Early StageTotal Funding
$300M2024-08-16Series Unknown· $300M
Leadership Team
J
James Li
President
Recent News
Company data provided by crunchbase